全文获取类型
收费全文 | 783篇 |
免费 | 84篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 53篇 |
妇产科学 | 35篇 |
基础医学 | 96篇 |
口腔科学 | 12篇 |
临床医学 | 61篇 |
内科学 | 152篇 |
皮肤病学 | 5篇 |
神经病学 | 40篇 |
特种医学 | 59篇 |
外科学 | 28篇 |
综合类 | 8篇 |
预防医学 | 40篇 |
眼科学 | 61篇 |
药学 | 152篇 |
肿瘤学 | 66篇 |
出版年
2023年 | 1篇 |
2022年 | 6篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 13篇 |
2017年 | 12篇 |
2016年 | 9篇 |
2015年 | 19篇 |
2014年 | 26篇 |
2013年 | 21篇 |
2012年 | 18篇 |
2011年 | 17篇 |
2010年 | 16篇 |
2009年 | 30篇 |
2008年 | 36篇 |
2007年 | 20篇 |
2006年 | 32篇 |
2005年 | 29篇 |
2004年 | 28篇 |
2003年 | 24篇 |
2002年 | 38篇 |
2001年 | 35篇 |
2000年 | 30篇 |
1999年 | 28篇 |
1998年 | 31篇 |
1997年 | 37篇 |
1996年 | 33篇 |
1995年 | 23篇 |
1994年 | 29篇 |
1993年 | 27篇 |
1992年 | 30篇 |
1991年 | 29篇 |
1990年 | 14篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 7篇 |
1985年 | 12篇 |
1984年 | 7篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 5篇 |
1970年 | 1篇 |
1902年 | 1篇 |
排序方式: 共有869条查询结果,搜索用时 31 毫秒
1.
2.
Rik C. Schoemaker Joop M. A. van Gerven Adam F. Cohen 《Journal of pharmacokinetics and pharmacodynamics》1998,26(5):581-593
The most widely applied model relating drug concentrations to effects is the Emax
model. In practice, concentration–effect relationships often deviate from a simple linear relationship but without reaching a clear maximum because a further increase in concentration might be associated with unacceptable or distorting side effects. The parameters for the Emax
model can only be estimated with reasonable precision if the curve shows sign of reaching a maximum, otherwise both EC50
and Emax
estimates may be extremely imprecise. This paper provides a solution by introducing a new parameter (S0
) equal to Emax/EC50
that can be used to characterize potency adequately even if there are no signs of a clear maximum. Simulations are presented to investigate the nature of the new parameter and published examples are used as illustration. 相似文献
3.
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
6.
G van Ingen J Schoemaker J P Baak 《Pathology, research and practice》1991,187(2-3):362-70; discussion 370-2
An androgen-secreting adnexal tumour is presented. The tumour was a steroid cell tumour of the mesovarium, without crystals of Reinke, hence the diagnosis was a steroid cell tumour (lipid cell tumour), not otherwise specified (in this case, because of its location in the mesovarium, an adrenal rest tumour). The clinical presentation, diagnosis, prognosis and differential diagnosis of virilizing adnexal tumours are discussed. 相似文献
7.
8.
S Z Langer H Schoemaker 《Progress in neuro-psychopharmacology & biological psychiatry》1988,12(2-3):193-216
1. Using [3H]antidepressants, high affinity binding sites associated with the neuronal transporter for serotonin, noradrenaline, dopamine and adrenaline have been identified. 2. The association of high affinity [3H]imipramine binding with the serotonin transporter in brain and platelets is well established. Although the exact relationship between the [3H]imipramine recognition site and the serotonin transporter remains to be elucidated, it appears that the [3H]imipramine labelled component of the serotonin transporter represents a novel receptor that functions to modulate serotonin uptake. 3. Most data available to date support the hypothesis that [3H]imipramine binding to platelet represents a biological marker in depression. The majority of studies indicate that the Bmax of platelet [3H]imipramine binding is lower in depressed, untreated patients than in the control population and that this finding is relatively specific to depression. 4. Among the [3H]antidepressant binding sites associated with the other monoaminergic transporters, the recent identification of [3H]desipramine binding to the neuronal transporter for adrenaline offers novel perspectives. Thus, given the high affinity for [3H]desipramine binding to the adrenaline transporter in the frog heart for not only desipramine but also imipramine and the atypical antidepressants mianserin and iprindol, it is possible that an interaction with the adrenaline transporter is of significance to the clinical effects of antidepressant drugs. 相似文献
9.
10.
Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. 总被引:1,自引:0,他引:1 下载免费PDF全文
J N van den Anker W C Hop R C Schoemaker B J van der Heijden H J Neijens R de Groot 《British journal of clinical pharmacology》1995,40(5):439-443
1. The effects of postnatal age and postnatal exposure to indomethacin on the pharmacokinetic parameters of ceftazidime (CAZ) were investigated in 23 preterm infants (gestational age 28.7 +/- 1.7 weeks; weight 1086 +/- 311 g) on day 3 and day 10 after birth. 2. CAZ (25 mg kg-1) was administered by intravenous bolus injection. Blood samples were drawn from an arterial catheter at 0, 0.5, 1, 2, 4, 8, and 12 h after the dose and CAZ concentrations in serum were determined by h.p.l.c. CAZ pharmacokinetics followed a one-compartment open model. 3. The glomerular filtration rate (GFR) of all infants was studied by means of the 24 h continuous inulin infusion technique. 4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth. Clearance of CAZ increased with increasing GFR (r = 0.81, P < 0.001). 5. In infants with postnatal exposure to indomethacin the changes in CAZ pharmacokinetics were markedly reduced. 6. These results indicate that the dosage regimen of CAZ should be adjusted after the first week of life except in infants who were postnatally exposed to indomethacin. 相似文献